首页> 外文期刊>JAMA oncology. >Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma The GEMCAD 1402 Randomized Clinical Trial
【24h】

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma The GEMCAD 1402 Randomized Clinical Trial

机译:FOLFOX6 Aflibercept +效果修改诱导化疗之前的标准化疗和手术患者高风险直肠腺癌GEMCAD 1402随机临床试验

获取原文
获取原文并翻译 | 示例
           

摘要

IMPORTANCE Preclinical studies suggest that a vascular endothelial growth factor (VEGF) blockade may play a role in the preoperative treatment of rectal adenocarcinoma; however, how to combine anti-VEGF drugs with neoadjuvant chemotherapy (CT) and/or chemoradiotherapy (CRT) remains controversial.
机译:临床前研究表明,重要性血管内皮生长因子(VEGF)封锁在术前可能发挥作用治疗直肠腺癌;结合抗vegf与新辅助药物化疗(CT)和/或化疗(CRT)仍然是有争议的。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号